Jan 4 (Reuters) - A federal judge on Wednesday said Botox maker AbbVie's ABBV.N Allergan unit can move ahead with its lawsuit accusing Revance Therapeutics RVNC.O of taking its confidential data to ...

Migraine episodes are tough, but the women who fight through them are tougher. That’s the message from Allergan in its evolved Botox for chronic migraine marketing. New TV ads, first begun in the fall ...

Allergan PLC’s multibillion-dollar Botox franchise is once again under attack from new competitors, threatening a core business at a time when the drugmaker is already battling other challenges. The ...

Last week, Allergan CEO Brent Saunders told investors that Botox “continues to remain very strong” in migraine despite the arrival of three drugs from the brand-new CGRP class. But exactly how strong?

CHICAGO (Reuters) - Allergan Inc said on Thursday that its popular Botox facial wrinkle-smoother worked as a treatment for adults suffering from chronic migraines, according to late-stage clinical ...

The current stock price likely implies Botox declines, but we think the franchise can maintain healthy growth as a result of expansion of the market and limited price competition. Firms Likely to Have ...

When patients come into the Palo Alto, CA, offices of facial plastic surgeons Drs. David M. Lieberman, MD, and Sachin S. Parikh, MD, they aren’t necessarily concerned with the authenticity of their ...

We’re adding branded drug giant Allergan (AGN), which is based in Ireland, to our model portfolio, says biotech and healthcare sector expert Bret Jensen, editor of Investors Alley’s Biotech Gems.

Jan 29 () - Allergan Plc on Tuesday forecast 2019 revenue below expectations on looming competition for some of its top drugs, and shelved plans to sell its women's health business. The Botox maker's ...

Every time Tanya publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...

Shares of Allergan plc Ordinary Shares AGN continue trading near their multi year low of $160.07, with many investors concerned with a competitive environment that will intensify in the coming years.

The anti-wrinkle drug Botox dramatically lifted Allergan Inc.’s first-quarter earnings but couldn’t smooth out Wall Street’s concerns about the rest of the year. Allergan said Monday that quarterly ...